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Alternative splicing of the Alxheimer’s amyloid /I protein precursor (ABPP) message leads to the production of several variants of this precursor 
polypeptide. Two of these variants contain a domain that is highly homologous to members of the Kunitz class of protease inhibitors. In order 
to initiate a study of the physiological role of this domain, we have produced active ABPP Kunitx inhibitor by constructing and expressing a syn- 
thetic gene in E. coli. Nerve growth factor (NGF) deficiency has been suggested as a possible cause of the neural degeneration characteristic of 
Alxheimer’s disease, and trypsin and y-NGF are the two enzymes that have been shown to be capable of processing /3-NGF precursor to active, 
mature B-NGF in vitro, therefore the specificity of purified recombinant ABPP Kunitx inhibitor was analyzed with respect o these two proteases. 
Binding of isolated ABPP Kunitx domain both to trypsin (Z&r < 10 nM and to y-NGF (R&s = 300 nM) was observed. This difference in binding 
to the two proteases correlates with the approximately 20-fold higher rate observed for in vitro processing of the j_-NGF precursor by trypsin 
compared to processing by y-NGF, indicating that perhaps the inhibitor mimics the interaction of the b-NGF precursor with proteases. The kalli- 
krein actually responsible for B-NGF precursor processing in vivo is unknown, but these results suggest hat it is capable of being significantly 
inhibited by exposure to the ABPP Kunitz domain. 
Alxheimer’s disease; Amyloid j3 protein; Kunitz inhibitor; Kallikrein; Nerve growth factor 
1. INTRODUCTION 
Alzheimer’s disease and trisomy 21 (Down’s syn- 
drome) are almost invariably associated with the 
deposition of neuritic plaque in the brains of stricken 
individuals. The precursor of the major polypeptide 
found in plaque, amyloid 0 protein, has recently been 
characterized by cDNA cloning [l-3]. Several different 
mRNAs exist, all splicing variants of a transcript deriv- 
ed from a single gene, and these appear to encode 
precursors 695,75 1 and 770 amino acids in length [l-3]. 
The messages encoding the two larger precursors have 
an additional exon spliced into the interior of the coding 
region, and the translated sequence of this exon sug- 
gests that it encodes a protein domain that is a member 
of the Kunitz class of protease inhibitors [4]. Consistent 
with this prediction, trypsin inhibitory activity was 
found in conditioned medium from cells transfected 
with amyloid /3 protein precursor (ABPP) cDNA con- 
taining the inhibitor sequences [3,5]. The Kunitz in- 
hibitor domain from ABPP has been highly conserved 
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in evolution [6,7], and thus it is likely that this domain 
plays a functionally significant role in vivo. Based on 
the known properties of the Kunitz inhibitor family, 
this role almost certainly involves stoichiometric 
binding to the active site of some endogenous protease 
or esterase 141. 
Nerve growth factor (NGF), NGF mRNA, NGF 
receptors, as well as NGF-related neurotrophic factors, 
have been found in the brains of adult mammals, sug- 
gesting that NGF-like molecules play a physiologically 
significant role in normal adult brain [8-l 11. Ex- 
ogenously adminstered NGF has also been shown to be 
capable of preventing degeneration of cholinergic 
neurons and associated memory loss in adult animals 
with experimentally induced lesions [ 121. Because 
Alzheimer’s disease is associated with neuronal cell 
loss, including those in the ascending cholinergic 
pathways of the basal forebrain [8], and because in- 
traventricular administration of anti-NGF antisera in 
experimental animals produces Alzheimer’s-like 
histological changes in the brain [13], it has been 
hypothesized that NGF deficiency may be causally 
related to the pathogenesis of Alzheimer’s disease [8]. 
The active neurotrophic factor, fl-NGF, is produced 
from relatively inactive precursor via proteolytic 
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processing [14-161. Thus the production of endogenous 
NGF activity in the brain presumably depends on the 
action of a kallikrein on the &NGF precursor, and 
disruption of this post-translational processing step 
should result in a decrease in active NGF. It is con- 
ceivable that a pathological state, manifested by poor 
neuron viability, could result from inappropriate ex- 
pression or cell localization of the amyloid Kunitz in- 
hibitor domain if this caused it to inhibit the processing 
enzyme for P-NGF activation. Similar proteolytic 
processing also appears to be necessary for the matura- 
tion of other NGF-like neurotrophic factors [9-l 11, so 
the actions of these should likewise be susceptible to in- 
terference by this mechanism. 
In order to begin testing the feasibility of this 
hypothesis we have prepared active ABPP Kunitz do- 
main inhibitor by expressing a synthetic coding se- 
quence for the inhibitor using an E. coli secretion vec- 
tor. We present here the results of binding studies with 
this isolated inhibitor domain and the two proteases, 
trypsin and y-NGF, that have been shown to be capable 
of correctly processing the &NGF precursor in vitro 
[14,15]. 
2. MATERIALS AND METHODS 
2.1. Synthetic Kunitz inhibitor coding sequences 
Eight oligodeoxynucleotides (Fig. lA), representing the duplex 
coding sequence for the Kunitz domain of the Alzheimer’s amyloid B 
protein precursor (codons 287-344 according to the numbering of [l]), 
were synthesized by the deoxynucleoside H-phosphonate method 
[17]. Codon choice was governed by an avoidance of codons known 
to be poorly expressed in E. coli [IS] or codons that would result in 
strong secondary structural features (e.g. hairpins) in the synthetic 
gene transcript. In addition, the oligonucleotides were designed to 
yield a MIuI site just upstream of the Kunitz inhibitor coding sequence 
and tandem stop codons followed by a San site at the 3’-end of the 
coding sequence (Fig. 1A). 
2.2. Expression of the synthetic Kunitz inhibitor gene 
EcoRI/MluI fragment containing the alkaline phosphatase pro- 
moter a ribosome binding site, and the ST11 signal sequence [19-211 
was isolated from pST2A. Plasmid pST2A (kindly provided by D. 
Henner, Genentech) is a derivative of phGH4R [21] in which codons 
20-22 of the ST11 signal sequence, AAT-GCC-TAT (Asn-Ala-Tyr) 
[19,20], were modified by site-directed mutagenesis to introduce a 
unique MluI site, AAC-GCG-TAT. A 4.2 kbp EcoRI/San fragment 
was isolated from the vector ~651 (C.B. Marks, unpublished); this 
fragment is identical in sequence to the 3.7 kbp EcoRI/San fragment 
from pBR322, except for a 0.45 kbp RsaI/_4haIII fragment contain- 
ing the phage fl + strand origin [22] inserted at the pBR322 PvuII 
site. Two pmols of each of the oligonucleotides comprising the syn- 
thetic ABPP Kunitz domain coding sequence were phophorylated 
with rATP and T4 polynucleotide kinase in 70 mM Tris-HCl (PH 7.8), 
10 mM MgClz, 5 mM dithiothreitol, then mixed, heated to 95’C, and 
cooled slowly to anneal the strands. The annealled oligonucleotides 
were mixed with the 0.52 kbp EcoRI/MluI fragment from pST2A and 
the 4.2 kbp EcoRI/SalI fragment from p65 1, and these were joined by 
incubating them in the same buffer as above with rATP and T4 DNA 
ligase. The ligation mixture was used to transform MM294 cells and 
random colonies were picked for preparation of single-stranded 
plasmid DNA using the M13K07 helper phage [23]. DNA isolates 
were screened for the presence of the inserted synthetic DNA by 
208 
dideoxy DNA sequencing [24] and one isolate, termed pSalz1 
(Fig. IB), was chosen for further characterization. pSalz1 was check- 
ed by dideoxy DNA sequencing of both strands to ensure that the in- 
serted synthetic DNA sequence was correct. E. coli W31 IOtonAtolA, 
transformed with pSAlz1, was grown in low phosphate medium as 
described previously [21]. 
2.3. Purification and characterization of recombinant ABPP 
Kunitz inhibitor domain 
Initial purification of the ABPP Kunitz inhibitor domain was car- 
ried out as previously described for E. co&derived bovine pancreatic 
trypsin inhibitor (BPTI) [25,26], except that the acid precipitation 
step was performed with one-percent trichloroacetic acid, and elution 
of the inhibitor from the trypsin-Sepharose affinity column was with 
10 mM HCl, 0.5 M KCI. Final purification was by Mono Q FPLC 
anion exchange chromatography with a 0.0-0.25 M gradient of NaCl 
in 20 mM Tris (pH 8.0), or by Superose 12 gel filtration 
chromatography in 150 mm NHdHCOs. A sample of the purified in- 
hibitor was subjected to 31 cycles of Edman degradation on an Ap- 
plied Biosystems 470A Protein Sequencer. The N-terminal sequence 
deduced was VREVXSEQAETGPXRAMISRWYFDVTEGKXA. 
Amino acid analyses were performed using the method of Meltzer et 
al. [27] on independent samples purified by Mono Q anion exchange 
and Superose 12 gel filtration chromatography. The following com- 
position, averaged from determinations on two independently 
purified samples, was found (theoretical values in parentheses): Asx, 
5.02* 0.07 (5); Ser, 2.63 kO.03 (3); Gly, 7.39kO.08 (7); Glx, 
6.7OkO.36 (7); Thr, 2.88kO.02 (3); Ala, 5.29kO.06 (5) Val, 
4.01&0.14 (4); Met, 1.74~tO.05 (2); Tyr, 3.13kO.02 (3); Ile, 
0.98kO.03 (1); Leu, 0.0 (0); Phe, 4.2OrtO.07 (4); His, 0.0 (0); Trp, 
0.85 f 0.05 (1); Lys, 1 .OO& 0.08 (1); Arg, 4.23 f 0.04 (4); Pro, ND (2); 
Cys, ND (6) (ND = not determined). 
2.4. Inhibition studies 
The molar concentration of purified recombinant ABPP Kunitz 
domain inhibitor in a reference solution was determined by quan- 
titative amino acid analysis, assuming a molecular mass of 6415 Da. 
BPTI (a gift from Miles Laboratories) was quantitated based on the 
published extinction coefficient at 280 nm of 0.84 for a 1 mg/ml solu- 
tion 1281. Trypsin was purchased from Boehringer-Mannheim. 
Murine 7S NGF (Sigma) was activated by incubating it for 24 h at 5°C 
in 50 mM Tris-HCl (pH 7.4), 1 mM EDTA. Activating 7S NGF in this 
manner uncovers the r-subunit esteropeptidase activity, resulting in a 
reactivity towards substrates and protease inhibitors that is in- 
distinguishable from the reactivity of the purified -y-subunit [29-311. 
Trypsin and -y-NGF activities were quantitated using the burst titrant 
p-nitrophenyl p’-guanidinobenzoate [32,33]. Aliquots containing 
0.1025 fl of enzyme were incubated for at least 15 min in 50 mM 
Tris-HCI (pH 7.4) with various concentrations of the purified ABPP 
Kunitz domain or BPTI, then 25 d of 16 mg/ml N-cr-benzoyl-DL- 
arginine-p-nitroanilide was added and the change in absorbance at 
405 nm was monitored at 25°C as a function of time. Reaction 
volumes were 1 ml. 
3. RESULTS 
Oligonucleotides representing codons 287-344 of 
ABPP,51 [l] were ligated together and fused to a gene 
fragment encoding the heat-stable nterotoxin II (STII) 
signal sequence in an E. co/i secretion vector (Fig. 1). 
This was done in such a way as to place the ABPP 
Val-287 residue (corresponding to residue one of the 
Kunitz inhibitor homologue, bovine pancreatic trypsin 
inhibitor (BPTI) [4,28]) on the C-terminal side of the 
signal peptidase cleavage site; tandem TAA stop codons 
were placed after the Ala-344 residue (Fig. 1). When ex- 
Volume 267, number 2 FEBS LETTERS July IWO 
Arg Ala Met Ile Ser Arg Tfp Tyr Phe Asp Val Thr Glu Gly Lys Cys 
35 40 45 50 55 





0 ~651 Sol I ~mpR (AholIl/P~ fl + strand on 
(flu II! Rso I) 
EcoR I 
I 
EroR I 0 52 kbp fragment 
+ 4 2 kbp fragment + 






Fig. 1. Expression of the ABPP Kunitz inhibitor domain. (A) Shown is the construction of the synthetic duplex coding sequence for the ABPP 
Kunitz inhibitor domain. The numbering is based on that of the homologous inhibitor, BPTI [25,28], and starts with the residue corresponding 
to Val-287 of ABPPr5r [l]. The sites where oligonucleotides were joined in the ligation reaction are indicated by filled triangles. The signal peptidase 
cleavage site between the ST11 leader peptide and the Kunitz inhibitor sequences i  indicated by a vertical arrow. Also shown are the MM and 
Sun hen&sites at the termini of the DNA fragment. (B) The expression vector, pSAlz1, was constructed via a three-way ligation of the synthetic 
MluI/SulI fragment, an EcoRI/MluI fragment containing the alkaline phosphatase promoter and the ST11 signal peptide coding sequences, and 
an EcoRI/SufI fragment containing the plasmid and fl phage replication origins and the ,%lactamase gene from plasmid pBR322. 
pressed in E. coli this construct produced detectable 
levels of secreted trypsin inhibitory activity. This activi- 
ty was purified to homogeneity from the culture 
medium by trichloroacetic acid precipitation, trypsin- 
Sepharose affinity chromatography, and Mono Q 
anion exchange or Superose 12 gel filtration FPLC 
[25,26]. Amino acid analysis of the purified material 
yielded results consistent with the predicted composi- 
tion of the ABPP Kunitz inhibitor, and 31 cycles of N- 
terminal amino acid sequencing yielded the predicted 
sequence and showed that no detectable internal clips 
were present. The disulfide bonding pattern for the 
recombinant ABPP Kunitz inhibitor was not determin- 
ed. However, an X-ray crystallographic analysis of the 
ABPP Kunitz inhibitor tertiary structure (R. Hynes and 
A. Kosiakoff, personal communication) showed that 
the disulfides were identical to the CysS-CysSS/Cysl4- 
Cys38/Cys30-Cys51 pattern observed in natural BPTI 
as well as in E. coli-derived BPTI produced by a similar 
system ([25,28] C.B.M., B.N. and S.A., unpublished). 
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Fig. 2. Inhibition of y-NGF and trypsin by recombinant ABPP 
Kunitz domain. The y-NGF esteropeptidase of 7s murine NGF (ac- 
tivated as described in section 2) or bovine trypsin were incubated 
with various concentrations of the ABPP Kunitz inhibitor domain at 
a constant enzyme concentration of 0.1025 PM. The activity of un- 
bound enzyme was monitored by measuring the change in absorbance 
at 405 nm due to BAPA hydrolysis as a function of time (see section 
2). The percent residual activity is graphed as a function of the in- 
hibitor : enzyme ratio; the closed symbols represent he data for y- 
NGF and the open symbols the data for trypsin. The insert shows the 
data at low inhibitor: enzyme ratios with the dashed line indicating the 
theoretical inhibition curve that would be produced by an inhibitor 
binding stoichiometrically to the enzyme with infinitely high affinity 
[36]. Apparent inhibtion constants (y-NGF, K,,,,, = 3.0 x lo-’ M; 
trypsin, K,,,, < 1 .O x 10-s M) were derived from these data using the 
equation [I]/(l-a) = K,,,,,(l/a) + [El, where [I] is the inhibitor con- 
centration, [E] the enzyme concentration, and a the residual activity 
[36,37] or by the method of Green and Work 1381. Similar binding ex- 
periments performed on y-NGF and trypsin with BPTI (not shown) 
yielded results consistent with published inhibition data for these 
complexes [28,31]. 
In the murine 7S NGF complex the y-subunit is inac- 
tive because its active site is complexed with the C- 
terminal arginine of the P-subunit [34]. To obtain free 
y-NGF the complex was dissociated in 50 mM Tris-HCI 
(pH 7.4), 1 mM EDTA [29-311. Aliquots of this were 
incubated with different concentrations of the purified 
ABPP Kunitz inhibitor, then added to N-a-benzoyl- 
DL-arginine-p-nitroanilide. The proportion of free en- 
zyme was determined by a spectrophotometric deter- 
mination of the relative ester hydrolysis rate. 
Esteropeptidase activity decreased with increasing 
amounts of inhibitor (Fig. 2). The apparent dissocia- 
tion constant for y-NGF and the ABPP Kunitz in- 
hibitor was determined from these data to be approx- 
imately 300 nM [35-371. 
Similar inhibition experiments with trypsin indicated 
that the ABPP Kunitz domain bound to this enzyme 
with an affinity significantly higher than its affinity for 
r-NGF (Fig. 2). The apparent dissociation constant for 
trypsin and the ABPP Kunitz inhibitor was estimated 
by the method of Green and Work [38] to be less than 
10 nM. 
4. DISCUSSION 
The etiology of Alzheimer’s disease is obscure. 
Research efforts in this area have primarily focussed on 
the phenomenon of neuritic plaque deposition [39,40] 
and on the possible role of trophic factors, e.g. nerve 
growth factor (NGF), in preventing the neuropatho- 
logical changes observed [8]. Some linkage between 
these two approaches has been suggested by the recent 
cDNA cloning of the precursor for the amyloid /3 pro- 
tein [l-3 1, the major polypeptide component of neuritic 
plaque. The sequence of this amyloid ,6 protein precur- 
sor (ABPP) has led to the discovery of several new 
bioactive protein fragments, some of which have 
trophic [41,42] or neurocytopathic [43] effects. The 
ABPP clones also reveal that the transcript for the 
precursor is alternatively spliced, resulting in at least 
two message species with an additional exon in the 
coding region. The amino acid sequence of this alter- 
natively spliced exon is homologous to members of the 
Kunitz class of protease inhibitors [l-4]. 
In this paper we have shown that the ABPP Kunitz 
inhibitor binds to and inhibits the two proteases, tryp- 
sin and -r-NGF, that have been shown to be capable of 
correctly processing the inactive P-NGF precursor in 
vitro [14,15]. Inhibition of trypsin by the ABPP Kunitz 
domain is strong, and inhibition of y-NGF relatively 
weak although still significant (Fig. 2). This inhibition 
spectrum correlates well with the relative efficiencies 
with which these two proteases process the P-NGF 
precursor: trypsin is approximately 20-fold more active 
than y-NGF in this reaction [14]. Thus, the specificity 
of the ABPP Kunitz domain may reflect the structure of 
the /3-NGF precursor, with the inhibitor:protease com- 
plex mimicking the substrate:enzyme interaction of 
prop-NGF with kallikrein(s). 
The ABPP Kunitz domain may function normally as 
part of a feedback control mechanism that modulates 
the production of active NGF and other growth factors 
(Fig. 3). It has been reported that high levels of 
inhibitor-containing ABPP restrict cell growth when 
added to the medium of ABPP-deficient fibroblasts, 
while the same levels of ABPP lacking the inhibitor do- 
main do not exhibit this effect [42]. 
Whether the ABPP Kunitz inhibitor actually inhibits 
the kallikrein-mediated processing of ,6-NGF precursor 
in vivo is unknown. The /3-NGF precursor expressed via 
a vaccinia virus vector in a variety of cell types is 
processed to mature NGF prior to secretion 1161. This 
indicates not only that the processing enzymes are 
unlikely to be cell-specific, but also that the processing 
occurs intracellularly in secretory granules or in the 
Golgi apparatus. This compartmentalization may pre- 
vent free, extracellular ABPP Kunitz inhibitor from 
contacting the processing enzymes. However, in cells 
synthesizing both ABPP and growth factor, the Kunitz 
domain could down-regulate growth factor maturation 
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Fig. 3. Model for how the Kunitz domain could modulate production 
of active neurotrophins in the brain. ABPP is shown as a membrane- 
associated polypeptide (adapted from [3]) although it also is found as 
a secreted protein [5&l-46]. The amyloidfl protein (A4) peptide is in- 
dicated by cross-hatching, and the N-terminal neurotrophic peptide 
[41] and the alternatively spliced Kunitz domain are also shown. The 
example given is for a negative-feedback loop regulating ,f3-NGF pro- 
duction. In addition to modulating nerve cell viability, ,&NGF in- 
creases ABPP gene expression [53]. The increased levels of the 
amyloid /3 protein precursor may then down-regulate P-NGF natura- 
tion if the alternatively spliced Kunitz inhibitor domain is present and 
binds to the kallikrein(s) that proteolytically process the growth factor 
precursor. 
if it were sorted to the same compartment as the growth 
factor precursor. 
Conceivably, secreted ABPP [5,44-461 could also in- 
hibit growth factor maturation by binding to specific 
cell-surfacte receptors via the N-terminal domain 
(Fig. 3) and being transported to the processing site of 
the growth factor precursor after internalization. 
Resialylation of asialo cell surface receptors has 
demonstrated that there are pathways in the cell which 
allow traffic of membrane proteins from the plasma 
membrane to the Golgi [47,48]. 
Recently, Oltersdorf et al, [5] and Van Nostrand et 
al. [49] have reported that the Kunitz domain- 
containing ABPP was identical to protease nexin II, a 
protease inhibitor secreted from fibroblasts [50]. Pro- 
tease nexin II has been shown to bind to trypsin, y- 
NGF, EGF binding protein, and chymotrypsin [49, 501, 
suggesting that the results we have obtained with the 
isolated ABPP Kunitz domain also apply to the 
behavior of the Kunitz domain in the context of the in- 
tact amyloid p protein precursor. Van Nostrand and 
Cunningham [50] have reported that protease nexin II 
does not form a stable complex with plasma kallikrein 
or plasmin, both of which bind to BPTI [28]. This in- 
dicates that the specificity of the ABPP Kunitz inhibitor 
may be greater than that of BPTI, consistent with its 
proposed role as an inhibitor of specific growth factor 
processing enzymes. It also suggests that the ABPP 
Kunitz inhibitor could be used as an affinity ligand for 
the purification and characterization of such enzymes. 
Recently a high resolution three-dimensional struc- 
ture has been determined for the ABPP Kunitz in- 
hibitor by X-ray crystallography (R. Hynes and A. 
Kossiakoff, personal communication). One striking dif- 
ference between the ABPP Kunitz domain structure 
and the BPTI structure is in the region of residues 38-40 
where the backbone adopts a different conformation in 
the two molecules. The sequence at these residues, Cys- 
Gly-Gly (Fig. l), in the ABPP Kunitz inhibitor allows it 
to adopt the alternative backbone fold, and this region 
overlaps the reactive site and specificity determining 
residues of the inhibitor [28]. It is intriguing that this 
same sequence motif commonly occurs in the den- 
drotoxins, which are neurotoxic members of the Kunitz 
inhibitor family isolated from mamba venoms [5 1,521. 
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